Does the media refer more to NUVB or TECX?

In the previous week, Tectonic Therapeutic had 7 more articles in the media than Nuvation Bio. MarketBeat recorded 8 mentions for Tectonic Therapeutic and 1 mentions for Nuvation Bio. Tectonic Therapeutic's average media sentiment score of 1.12 beat Nuvation Bio's score of 0.67 indicating that Tectonic Therapeutic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tectonic Therapeutic 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, BHVN or TECX?

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$4.64 N/A Tectonic Therapeutic N/A N/A -$74.15M -$4.57 N/A

Is BHVN or TECX more profitable?

Tectonic Therapeutic's return on equity of -35.26% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -1,328.94% -138.27% Tectonic Therapeutic N/A -35.26% -33.59%

Does the media prefer BHVN or TECX?

In the previous week, Tectonic Therapeutic had 1 more articles in the media than Biohaven. MarketBeat recorded 8 mentions for Tectonic Therapeutic and 7 mentions for Biohaven. Tectonic Therapeutic's average media sentiment score of 1.12 beat Biohaven's score of 0.97 indicating that Tectonic Therapeutic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Tectonic Therapeutic 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, PHVS or TECX?

Pharvaris is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharvaris N/A N/A -$198.79M -$3.05 N/A Tectonic Therapeutic N/A N/A -$74.15M -$4.57 N/A

Is PHVS or TECX more profitable?

Tectonic Therapeutic's return on equity of -35.26% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -61.40% -56.00% Tectonic Therapeutic N/A -35.26% -33.59%

Does the media prefer PHVS or TECX?

In the previous week, Pharvaris and Pharvaris both had 8 articles in the media. Pharvaris' average media sentiment score of 1.58 beat Tectonic Therapeutic's score of 1.12 indicating that Pharvaris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive Tectonic Therapeutic 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SRPT or TECX?

In the previous week, Sarepta Therapeutics had 6 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 14 mentions for Sarepta Therapeutics and 8 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 1.12 beat Sarepta Therapeutics' score of 1.07 indicating that Tectonic Therapeutic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tectonic Therapeutic 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PVLA or TECX more profitable?

Tectonic Therapeutic's return on equity of -35.26% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Palvella Therapeutics N/A -47.84% -38.33% Tectonic Therapeutic N/A -35.26% -33.59%

Does the media prefer PVLA or TECX?

In the previous week, Palvella Therapeutics had 4 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 12 mentions for Palvella Therapeutics and 8 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 1.12 beat Palvella Therapeutics' score of 1.11 indicating that Tectonic Therapeutic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tectonic Therapeutic 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tectonic Therapeutic (TECX) Competitors

$29.92 -0.46 (-1.51%)

As of 09/3/2026 04:00 PM Eastern

Compare

TECX vs. NUVB, BHVN, PHVS, SRPT, and PVLA

Should you buy Tectonic Therapeutic stock or one of its competitors? Tectonic Therapeutic's main competitors and comparable companies include Nuvation Bio (NUVB), Biohaven (BHVN), Pharvaris (PHVS), Sarepta Therapeutics (SRPT), and Palvella Therapeutics (PVLA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tectonic Therapeutic compare to Nuvation Bio?

Nuvation Bio (NYSE:NUVB) and Tectonic Therapeutic (NASDAQ:TECX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Nuvation Bio has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.31, suggesting that its share price is 231% more volatile than the broader market.

Tectonic Therapeutic has a net margin of 0.00% compared to Nuvation Bio's net margin of -88.18%. Tectonic Therapeutic's return on equity of -35.26% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-88.18%	-46.59%	-22.01%
Tectonic Therapeutic	N/A	-35.26%	-33.59%

61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Tectonic Therapeutic has lower revenue, but higher earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	37.57	-$204.63M	-$0.44	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A

Nuvation Bio currently has a consensus target price of $13.00, indicating a potential upside of 93.16%. Tectonic Therapeutic has a consensus target price of $77.25, indicating a potential upside of 158.19%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, analysts clearly believe Tectonic Therapeutic is more favorable than Nuvation Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Tectonic Therapeutic	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

In the previous week, Tectonic Therapeutic had 7 more articles in the media than Nuvation Bio. MarketBeat recorded 8 mentions for Tectonic Therapeutic and 1 mentions for Nuvation Bio. Tectonic Therapeutic's average media sentiment score of 1.12 beat Nuvation Bio's score of 0.67 indicating that Tectonic Therapeutic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tectonic Therapeutic	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tectonic Therapeutic beats Nuvation Bio on 12 of the 16 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Biohaven?

Biohaven (NYSE:BHVN) and Tectonic Therapeutic (NASDAQ:TECX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Biohaven has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.31, meaning that its share price is 231% more volatile than the broader market.

88.8% of Biohaven shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 13.8% of Biohaven shares are owned by insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Tectonic Therapeutic's return on equity of -35.26% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-1,328.94%	-138.27%
Tectonic Therapeutic	N/A	-35.26%	-33.59%

Biohaven currently has a consensus price target of $18.94, indicating a potential upside of 19.10%. Tectonic Therapeutic has a consensus price target of $77.25, indicating a potential upside of 158.19%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, analysts plainly believe Tectonic Therapeutic is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.65
Tectonic Therapeutic	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A

In the previous week, Tectonic Therapeutic had 1 more articles in the media than Biohaven. MarketBeat recorded 8 mentions for Tectonic Therapeutic and 7 mentions for Biohaven. Tectonic Therapeutic's average media sentiment score of 1.12 beat Biohaven's score of 0.97 indicating that Tectonic Therapeutic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Tectonic Therapeutic	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tectonic Therapeutic beats Biohaven on 10 of the 13 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and Tectonic Therapeutic (NASDAQ:TECX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Pharvaris has a beta of -2.33, meaning that its stock price is 333% less volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.31, meaning that its stock price is 231% more volatile than the broader market.

Pharvaris is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A

In the previous week, Pharvaris and Pharvaris both had 8 articles in the media. Pharvaris' average media sentiment score of 1.58 beat Tectonic Therapeutic's score of 1.12 indicating that Pharvaris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Tectonic Therapeutic	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharvaris presently has a consensus target price of $51.08, indicating a potential upside of 43.23%. Tectonic Therapeutic has a consensus target price of $77.25, indicating a potential upside of 158.19%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, analysts clearly believe Tectonic Therapeutic is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Tectonic Therapeutic	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Tectonic Therapeutic's return on equity of -35.26% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-61.40%	-56.00%
Tectonic Therapeutic	N/A	-35.26%	-33.59%

62.6% of Tectonic Therapeutic shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by company insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Tectonic Therapeutic beats Pharvaris on 10 of the 13 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Sarepta Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and Tectonic Therapeutic (NASDAQ:TECX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Sarepta Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.31, meaning that its stock price is 231% more volatile than the broader market.

In the previous week, Sarepta Therapeutics had 6 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 14 mentions for Sarepta Therapeutics and 8 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 1.12 beat Sarepta Therapeutics' score of 1.07 indicating that Tectonic Therapeutic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tectonic Therapeutic	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tectonic Therapeutic has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -13.48%. Sarepta Therapeutics' return on equity of -1.60% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%
Tectonic Therapeutic	N/A	-35.26%	-33.59%

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tectonic Therapeutic has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	1.10	-$713.41M	-$2.90	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A

Sarepta Therapeutics currently has a consensus price target of $25.06, indicating a potential upside of 9.00%. Tectonic Therapeutic has a consensus price target of $77.25, indicating a potential upside of 158.19%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, analysts plainly believe Tectonic Therapeutic is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	5 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.20
Tectonic Therapeutic	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Summary

Tectonic Therapeutic beats Sarepta Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Palvella Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and Tectonic Therapeutic (NASDAQ:TECX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Palvella Therapeutics has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.31, meaning that its share price is 231% more volatile than the broader market.

Palvella Therapeutics presently has a consensus target price of $209.14, indicating a potential upside of 34.52%. Tectonic Therapeutic has a consensus target price of $77.25, indicating a potential upside of 158.19%. Given Tectonic Therapeutic's higher possible upside, analysts plainly believe Tectonic Therapeutic is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Tectonic Therapeutic	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Tectonic Therapeutic's return on equity of -35.26% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-47.84%	-38.33%
Tectonic Therapeutic	N/A	-35.26%	-33.59%

40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 17.2% of Palvella Therapeutics shares are owned by company insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Palvella Therapeutics has higher revenue and earnings than Tectonic Therapeutic. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	52.33	-$41.72M	-$4.83	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A

In the previous week, Palvella Therapeutics had 4 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 12 mentions for Palvella Therapeutics and 8 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 1.12 beat Palvella Therapeutics' score of 1.11 indicating that Tectonic Therapeutic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tectonic Therapeutic	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tectonic Therapeutic beats Palvella Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Tectonic Therapeutic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TECX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TECX vs. The Competition

Export

Metric	Tectonic Therapeutic	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$593.91M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-6.55	12.66	273.29	25.38
Price / Sales	N/A	1,309.08	613.45	92.55
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	2.61	16.29	12.89	6.14
Net Income	-$74.15M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-16.00%	0.34%	0.60%	-0.27%
1 Month Performance	2.57%	8.52%	5.73%	0.68%
1 Year Performance	73.25%	52.66%	25.35%	14.84%

Tectonic Therapeutic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TECX Tectonic Therapeutic	3.0931 of 5 stars	$29.92 -1.5%	$77.25 +158.2%	+83.2%	$593.91M	N/A	N/A	120	Positive News Analyst Forecast
NUVB Nuvation Bio	3.6457 of 5 stars	$6.68 +0.3%	$13.00 +94.6%	+113.2%	$2.34B	$62.90M	N/A	60	Gap Up
BHVN Biohaven	2.5383 of 5 stars	$15.72 +2.9%	$18.94 +20.5%	-1.9%	$2.31B	N/A	N/A	239
PHVS Pharvaris	3.9751 of 5 stars	$34.93 +0.9%	$51.08 +46.2%	+62.8%	$2.26B	N/A	N/A	30	Positive News Short Interest Increase
SRPT Sarepta Therapeutics	2.4136 of 5 stars	$21.33 +1.4%	$25.06 +17.5%	+21.3%	$2.22B	$2.20B	N/A	1,372	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TECX) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tectonic Therapeutic (TECX) Competitors

TECX vs. NUVB, BHVN, PHVS, SRPT, and PVLA

How does Tectonic Therapeutic compare to Nuvation Bio?

Summary

How does Tectonic Therapeutic compare to Biohaven?

Summary

How does Tectonic Therapeutic compare to Pharvaris?

Summary

How does Tectonic Therapeutic compare to Sarepta Therapeutics?

Summary

How does Tectonic Therapeutic compare to Palvella Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECX vs. The Competition

Tectonic Therapeutic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tectonic Therapeutic (TECX) Competitors

TECX vs. NUVB, BHVN, PHVS, SRPT, and PVLA

How does Tectonic Therapeutic compare to Nuvation Bio?

Which has more volatility and risk, NUVB or TECX?

Is NUVB or TECX more profitable?

Do institutionals and insiders hold more shares of NUVB or TECX?

Which has stronger valuation & earnings, NUVB or TECX?

Do analysts rate NUVB or TECX?

Does the media refer more to NUVB or TECX?

Summary

How does Tectonic Therapeutic compare to Biohaven?

Which has more volatility & risk, BHVN or TECX?

Do institutionals & insiders hold more shares of BHVN or TECX?

Is BHVN or TECX more profitable?

Do analysts rate BHVN or TECX?

Which has better earnings and valuation, BHVN or TECX?

Does the media prefer BHVN or TECX?

Summary

How does Tectonic Therapeutic compare to Pharvaris?

Which has more risk and volatility, PHVS or TECX?

Which has higher valuation and earnings, PHVS or TECX?

Does the media prefer PHVS or TECX?

Do analysts rate PHVS or TECX?

Is PHVS or TECX more profitable?

Do insiders & institutionals hold more shares of PHVS or TECX?

Summary

How does Tectonic Therapeutic compare to Sarepta Therapeutics?

Which has more volatility and risk, SRPT or TECX?

Does the media prefer SRPT or TECX?

Is SRPT or TECX more profitable?

Do insiders and institutionals believe in SRPT or TECX?

Which has preferable earnings & valuation, SRPT or TECX?

Do analysts rate SRPT or TECX?

Summary

How does Tectonic Therapeutic compare to Palvella Therapeutics?

Which has more volatility & risk, PVLA or TECX?

Do analysts rate PVLA or TECX?

Is PVLA or TECX more profitable?

Do institutionals & insiders believe in PVLA or TECX?

Which has stronger valuation & earnings, PVLA or TECX?

Does the media prefer PVLA or TECX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECX vs. The Competition

Tectonic Therapeutic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools